SCHEMBL3368539

SCHEMBL3368539

CCN(c1ccccc1)c1ccc(-c2ccc(N(CC)c3ccccc3)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.55
MAPT P10636 4/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 4/20 0.43
TSHR P16473 3/20 0.43
GLA P06280 1/20 0.43
HPGD P15428 1/20 0.42
KDM4C Q9H3R0 1/20 0.41
APAF1 O14727 1/20 0.41
CASP3 P42574 1/20 0.41
CASP6 P55212 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TAAR1 Q96RJ0 1/20 0.40
AGTR1 P30556 1/20 0.40
CNR2 P34972 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18377018 0.98 NR3C2 (0.53) NR3C2MAPTCRHBPCRHR2NPSR1
SCHEMBL20160922 0.98 NR3C2 (0.53) NR3C2MAPTCRHBPCRHR2NPSR1
SCHEMBL6932587 0.98 NR3C2 (0.52) NR3C2MAPTCRHBPCRHR2NPSR1
SCHEMBL20681739 0.96 NR3C2 (0.51) NR3C2MAPTCRHBPCRHR2NPSR1
SCHEMBL9565100 0.95 NR3C2 (0.50) NR3C2MAPTCRHBPCRHR2NPSR1
SCHEMBL7149333 0.93 NR3C2 (0.60) NR3C2MAPTCRHBPCRHR2NPSR1
SCHEMBL409370 0.90 NR3C2 (0.57) NR3C2MAPTCRHBPCRHR2NPSR1
SCHEMBL6567347 0.90 NR3C2 (0.57) NR3C2MAPTCRHBPCRHR2NPSR1
SCHEMBL12763736 0.90 NR3C2 (0.47) NR3C2MAPTCRHBPCRHR2NPSR1
SCHEMBL21390743 0.90 NR3C2 (0.47) NR3C2MAPTCRHBPCRHR2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6532098-B1 Sandwiched between two electrically conductive substrates at least one of which is transparent; benzidine or phenylenediamine compounds, acryloyl-modified polyalkylene oxide; viologen compound NIPPON MITSUBISHI OIL CORPORATION (JP) 2003-03-11 US claimed
EP-1496044-B1 NOVEL 1,3,5-TRIS(ARYLAMINO)BENZENE BANDO CHEMICAL IND (JP) 2010-11-03 EP disclosed
US-7271291-B2 1,3,5-tris (arylamino) benzenes BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2007-09-18 US disclosed
US-7196224-B2 1,3,5-tris(arylamino)benzenes BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2007-03-27 US disclosed
US-20060173216-A1 Novel 1, 3, 5 tris (arylamino) benzenes BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2006-08-03 US disclosed
US-20050090692-A1 Novel 1,3,5-tris(arylamino)benzene BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2005-04-28 US disclosed
EP-1496044-A1 NOVEL 1,3,5-TRIS(ARYLAMINO)BENZENE Bando Chemical Industries, Ltd. (JP) 2005-01-12 EP disclosed
US-6532098-B1 Sandwiched between two electrically conductive substrates at least one of which is transparent; benzidine or phenylenediamine compounds, acryloyl-modified polyalkylene oxide; viologen compound NIPPON MITSUBISHI OIL CORPORATION (JP) 2003-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173216-A1 Novel 1, 3, 5 tris (arylamino) benzenes HSPA4L, HSPA1A, GAPVD1 NR3C2 4066/4885MAPT 1954/4885CRHBP 4801/4885
US-20050090692-A1 Novel 1,3,5-tris(arylamino)benzene AHR, MYB, NAP1L4 NR3C2 3801/4885MAPT 2513/4885CRHBP 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.